You are here
ABL and Indicia Biotechnology join forces to strengthen leadership in immuno-assays
- ABL acquires the Assay Development activities of Indicia Biotechnology
- With this transaction, ABL gets access to Indicia’s Immunoline™ proprietary platform and strengthens its position as a leader in immunomonitoring
- Indicia Biotechnology becomes one of the major shareholders of ABL
Lyon and Oullins, France, June 24, 2013 – ABL, a specialist in immunomonitoring services, and Indicia Biotechnology (“Indicia”), a company specialized in the development of bioassays, announce the signature of an agreement by which ABL will acquire the immuno-assays activities of Indicia.
With this acquisition, ABL enriches its service range solution to the biopharmaceutical, diagnostic and cosmetic industries. It notably gets access to Indicia’s Immunoline™ proprietary platform for immunogenicity risk assessment of biologics and its immuno-assay development expertise. This operation consolidates ABL’s unique services offer from assay development to the realization of complex clinical trials studies complying with high regulatory requirements, and will benefit ABL and Indicia’s customer portfolio.
All activities will be operated within ABL’s laboratories in the Center of Excellence for Infectious diseases of Lyon.